Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non-small-cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy. Here we report the results for the second primary end point of overall survival.We randomly assigned patients, in a 2:1 ratio, to receive durvalumab...